Bank of Montreal
PRLD icon

Bank of Montreal’s Prelude Therapeutics PRLD Stock Holding History

Bank of Montreal’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-300
Closed -$11K – 4641
2021
Q1 		$11K Sell
300
-1,134
-79% -$75.2K ﹤0.01% 4336
2020
Q4 		$98K Buy
+1,434
New +$71.3K ﹤0.01% 3599

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Bank of Montreal's PRLD Position: Q2 2021 in Review

Bank of Montreal sold out of Prelude Therapeutics (PRLD) in Q2 2021, closing a stake of 300 shares — an estimated $11K sold.

Bank of Montreal first reported a position in PRLD in Q4 2020 and held it in 2 quarters. The position peaked at $98K in Q4 2020. 57 funds tracked by Wall St. Rank hold PRLD as of Q2 2021.

  • Bank of Montreal reported no remaining Prelude Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Bank of Montreal sold 300 Prelude Therapeutics shares in Q2 2021, an estimated $11K.
  • Bank of Montreal first reported a position in Prelude Therapeutics in Q4 2020 and held it in 2 quarters.
  • Bank of Montreal's Prelude Therapeutics position peaked at $98K in Q4 2020.
  • 57 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2021.

Based on Bank of Montreal's 13F filing for Q2 2021, filed 12 Aug 2021.